BRIEF-Galapagos says eligible to get 34 mln euro milestone payment from GSK

BRUSSELS Wed Nov 27, 2013 1:57am EST

Related Topics

BRUSSELS Nov 27 (Reuters) - Galapagos NV : * Eligible to receive from GSK 34 million euros, and up to double-digit royalties on commercial sales of GSK2586184 * GSK to initiate exploratory phase 2 study with GSK2586184 in patients with ulcerative colitis * Ulcerative colitis is a third indication for this investigational molecule, in addition to psoriasis and lupus

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.